Meeting
2018 ASCO Annual Meeting
Peptide receptor radionuclide therapy (PRRT) transcriptomic signature in blood for prediction of 177lu-octreotate efficacy.
Authors
Lisa Bodei
Memorial Sloan Kettering Cancer Center, New York, NY
Lisa Bodei , Mark S. Kidd , Aviral Singh , Wouter A van der Zwan , Stefano Severi , Ignat Drozdov , Jaroslaw B Cwikla , Richard P. Baum , Dik J. Kwekkeboom , Giovanni Paganelli , Eric Krenning , Irvin Mark Modlin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Neuroendocrine/Carcinoid
Citation
J Clin Oncol 36, 2018 (suppl; abstr 4101)
DOI
10.1200/JCO.2018.36.15_suppl.4101
Abstract #
4101
Poster Bd #
290
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
The utility of blood-based molecular tools-the NETest-to monitor and evaluate the efficacy of PRRT in neuroendocrine tumors.
First Author: Lisa Bodei
Poster
2017 ASCO Annual Meeting
Blood measurements of neuroendocrine tumor (NET) transcripts and gene cluster analysis to predict efficacy of peptide radioreceptor therapy.
First Author: Lisa Bodei
Poster
2023 ASCO Annual Meeting
LANTana trial protocol: An open label, single arm, phase Ib study to evaluate the effect of pre-treatment with ASTX727 (a demethylating agent) followed by lutetium Lu 177 dotatate in patients with progressive, metastatic neuroendocrine neoplasias (NENs).
First Author: Rohini Sharma
Poster
2023 ASCO Gastrointestinal Cancers Symposium
ETCTN 10450: A phase I trial of peposertib and lutetium 177 DOTATATE in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
First Author: Aman Chauhan